ReviewFrontiers in endocrinology2024
Central and nephrogenic diabetes insipidus: updates on diagnosis and management.
Review in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Open-Label, Balanced, Randomized, Single-Dose, Three-Treatment, Three-Sequence, Three-Period, Three-Way Crossover Oral Bioequivalence Study of Desmopressin Acetate Oral Solution.Clinical pharmacology in drug development · 2026Trial
- Novel Roles of GPCRs in the Renal Collecting Duct.Physiology (Bethesda, Md.) · 2026Review
- Article
- Adipsic hypernatremia associated with hypothalamic dysfunction and sleep disorders.JCEM case reports · 2026Article
- Central Diabetes Insipidus as a Rare Cause of Polyuria.Annals of African medicine · 2026Article
- Clinical utility of copeptin in histiocytosis-associated arginine vasopressin deficiency: a report of three cases.Annals of hematology · 2026Article
- Repetitive Scuba Diving as a Novel Trigger for Diabetes Insipidus: A Case Report.Kidney international reports · 2026Article
- Renal dilatation masquerading as retroperitoneal tumors.JCEM case reports · 2026Article
- Arginine vasopressin disorders, formerly known as diabetes insipidus.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Identification of a novel large deletion mutation in theTranslational pediatrics · 2026Article
- First European case of Geller syndrome complicated with hypokalemic nephropathy: A case report and literature review.Metabolism open · 2026Review
- Sodium and Water Homeostasis in Children: Pathogenesis, Diagnosis, and Treatment.Journal of clinical medicine · 2026Review
- Drug spectrum and disproportionality signals for diabetes insipidus in FAERS: multi-method analysis, JADER cross-database assessment, and PubMed-based case-level evidence.Frontiers in pharmacology · 2026Article
- Severe Diabetic Ketoacidosis With Refractory Hypernatremia due to Hypokalemia-Induced Arginine Vasopressin Resistance: A Case Report and Literature Review.Case reports in medicine · 2026Article
- Infant Nephrogenic Diabetes Insipidus: Challenges Leading to Delayed Management.Case reports in medicine · 2026Article
- Development and validation of a prediction model for hypernatremia in patients with severe burns.Frontiers in medicine · 2026Article
- Haemostasis and beyond: The expanding role of desmopressin in intensive care.World journal of critical care medicine · 2025Review
- Beyond Biomarkers: Blending Copeptin and Clinical Cues to Distinguish Central Diabetes Insipidus from Primary Polydipsia in Children.Biomedicines · 2025Article
- Partial central diabetes insipidus during lithium use: A case report and literature review.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes insipidus (DI) is a rare endocrine disease involving antidiuretic hormone (ADH), encompassing both central and nephrogenic causes. Inability to respond to or produce ADH leads to inability of the kidneys to reabsorb water, resulting in hypotonic polyuria and, if lack of hydration, hypernatremia. DI cannot be cured and is an unfamiliar disease process to many clinicians. This diagnosis must be distinguished from primary polydipsia and other causes of hypotonic polyuria. The main branchpoints in pathophysiology depend on the level of ADH pathology: the brain or the kidneys. Prompt diagnosis and treatment are critical as DI can cause substantial morbidity and mortality. The gold standard for diagnosis is a water deprivation test followed by desmopressin administration. There is promising research regarding a new surrogate marker of ADH called copeptin, which may simplify and improve the accuracy in diagnosing DI in the future. Patients with DI require adequate access to water, and there are nuances on treatment approaches depending on whether a patient is diagnosed with central or nephrogenic DI. This article describes a stepwise approach to recognition, diagnosis, and treatment of DI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.